2025
November
MiTEs turn TAM suppression into T cell synergy
November 26, 2025
Inhibition or reprogramming of tumor-associated macrophages (TAMs) has great potential to improve the tumor immune environment, but has, so far, shown limited clinical efficacy. To improve macrophage-targeted therapies, von Locquenghien, Zwicky, Cie, et al. described their dual TAM- and T cell-targeting strategy in a recent Cell publication. Using publicly available datasets from human...
SITC - 40th Anniversary Annual Meeting 2025
November 19, 2025
The ACIR team attended the SITC - 40th Anniversary Annual Meeting 2025 in National Harbor, Maryland. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Keynote addressJennifer A. Wargo Richard V. Smalley Memorial AwardIra Mellman, PhD Epitopes and cancer vaccinesCatherine J. WuChristopher KlebanoffOlivera...
N17350: a cytotoxic cancer therapy that spares the immune system
November 12, 2025
Cytotoxic cancer treatments, like chemotherapy and radiation, have the potential to synergize with immunotherapies through direct killing of tumor cells, which leads to the release of antigens and damage-associated molecular patterns. However, this potential synergy is often hindered when indiscriminate cytotoxicity kills immune cells as well. To more selectively target cancer cells, Gujar...
COVID-19 mRNA vaccines provide a surprising boost to ICB therapy efficacy
November 5, 2025
Improving the efficacy of immune checkpoint blockade (ICB) for a larger group of patients, particularly those with immune-cold tumors, is one of the major goals of current immunotherapy research. Based on case reports of patients who had spontaneous tumor regression after receiving COVID-19 mRNA vaccines, Grippin, Marconi, Copling, Li, et al. investigated the...
